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ABSTRACT
The biological basis for the restricted immunogenicity of some live attenuated influenza vaccine strains generated 
on the backbone of the cold adapted (ca) A/Singapore/1/1957/ca (H2N2) influenza A virus master strain and 
produced in the Vero cells was investigated. According to our previous results the vaccine candidate made from 
A/Hong  Kong/1035/1998 (H1N1) Vero-derived virus did not provoke a measurable antibody titers following the intranasal 
immunization of humans. We report here that the hemagglutinin (HA) of A/Hong Kong/1035/1998 virus contained the mutation 
10Ile→Val in the HA2 subunit, that increased the pH threshold of HA conformational change (pH of activation) by 0.3 pH units 
and therefore might be responsible for the lack of immune response in humans. Similar effect was shown for the reassortant made 
from the Vero-derived A/Switzerland/5389/1995 (H1N1) (5389wt) virus which had the HA2 mutation 3Phe→Leu leading to the 
lack of immune response in mice. Another factor compromising the immunogenicity of a vaccine candidate is the incompatibility 
of epidemic virus HA with the M gene of the master strain. In mice the 6/2 A/Switzerland/5389/1995 reassortant induced 
antibodies that were directed predominantly to the HA2 subunit and were detectable by ELISA but not by a hemagglutination 
inhibition (HAI) test. In contrast, the 5/3 reassortant, bearing the HA, neuraminidase (NA), and M genes from the epidemic virus 
induced an equivalent amount of antibodies against the HA1 and HA2 subunits detected by HAI and ELISA. By comparing the 
sensitivity of the viruses to amantadine, we showed that the M2 ion channel of the master strain had lower activity than that of the 
A/Switzerland/5389/1995. These data suggest that M2 of the master strain was not sufficiently active to keep the pH of the trans-
Golgi network high enough to prevent the conformational change of the acid sensitive HA to the low pH form. 
Overall, the adaptation mutations in the HA of the vaccine candidate that increase the pH of HA activation as well as the 
incompatibility of HA and M genes must be taken into consideration when constructing the reassortant strains for the live 
attenuated vaccine. 
INTRODUCTION
Vaccination against influenza continues to be one of 
the most effective means to prevent the disease and to 
decrease the mortality rate during influenza epidemics. 
Inactivated and live attenuated vaccines are the two 
types of influenza vaccines available on the market. 
Currently, two live influenza vaccines are approved. First, 
an attenuated cold adapted (ca) vaccine was developed 
in Russia in the 1980s [1-5]. Later, a similar vaccine 
known by the trade name FluMist® was developed in 
the US using the same approach [6, 7]. The conventional 
vaccine strains for the live vaccine are virus reassortants, 
which combine two gene segments coding for surface 
glycoproteins hemagglutinin (HA) and neuraminidase 
(NA) derived from actual epidemic viruses with the 
six internal protein gene segments of the attenuated 
master strain (6/2 combination). These reassortants are 
created by classical reassortment (Russian vaccine) or 
by reverse genetics (FluMist®). The master strains used 
for both vaccines are H2N2 viruses attenuated by serial 
passages at a suboptimal temperature in embryonated 
hen’s eggs or primary chicken kidney cells. Both vaccines 
are produced in embryonated eggs. This production 
system has several shortcomings including inflexibility, 
cumbersome processing, potential of allergic reactions 
to residual egg protein, and the inability of some strains 
to grow to high titers in eggs. The major drawback of 
the egg production system is the selection of receptor-
binding mutants, which might have altered antigenic 
properties [8-10]. It is believed that the replacement of 
eggs by mammalian continuous cell lines could overcome 
the above-mentioned limitations. 
Several cell lines have been approved for the 
production of an influenza vaccine. The African green 
monkey kidney (Vero) and the Madin Darby canine 
kidney (MDCK) cell lines are considered to be the most 
prominent substrates for vaccine production [11, 12]. 
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The Vero cell line is very attractive because it was used 
for over 35 years for the production of polio and rabies 
virus vaccines for humans [13, 14]. Human influenza 
viruses grow to high yields in MDCK cells but do not 
reach high titers in Vero cells. It was found that Vero cells 
have a higher endosomal pH than MDCK cells [15]. The 
acidic environment of the endosome is necessary for the 
change of HA conformation to the low pH form in order 
to create the conditions for the subsequent fusion of the 
viral and endosomal membranes – the mandatory step 
for the delivery of the viral genome into the cytoplasm. 
Several adaptation passages are usually required to 
enable efficient influenza virus growth in Vero cells. 
A new cold adapted master strain for the cell line-
based influenza vaccine was generated by the adaptation 
of the virus A/Singapore/1/1957 (H2N2) to the growth 
on Vero cells at 25°C by serial passages. The resulting 
virus A/Singapore/1/1957/ca (Sing/ca) was shown to be 
attenuated for laboratory animals (mice and ferrets) 
[16]. Several vaccine candidates were obtained by the 
reassortment of Sing/ca with the epidemic viruses 
isolated directly in Vero cells. However, the preclinical 
experiments in mice and ferrets (unpublished data) as 
well as the clinical examination of the obtained strains 
revealed low immunogenicity for some of them. Thus, 
according to our previous data [16], the immunization of 
adult volunteers with the reassortant of wild type (wt) 
virus A/Switzerland/7729/1998 (H3N2) (7729wt) induced 
antibodies with the geometric mean titer (GMT) of 45.25 
in the hemagglutination inhibition (HAI) test, while the 
use of the reassortant of A/Hong Kong/1035/1998 (H1N1) 
(1035wt) virus did not provoke a measurable antibody 
titer. 
The goal of the current study was to investigate the 
biological basis for the restricted immunogenicity of 
some live attenuated influenza vaccine strains produced 
in the Vero cell line. 
MATERIALS AND METHODS 
Viruses and cells
Vero and MDCK cell lines were obtained from the 
American Type Culture Collection (ATCC). Vero cells 
were adapted to and further cultivated in DMEM/Ham’s 
F12 medium (Biochrom F4815) with 4 mM L-glutamine 
and animal protein free supplement (proprietary 
formulation, Polymun Scientific GmbH, Austria). MDCK 
cells were cultivated in DMEM/Ham’s F12 (1:1) medium 
supplemented with 2% of heat inactivated fetal calf 
serum (FCS) (Gibco).
Epidemic wild type viruses 5389wt (H1N1) and 7729wt 
(H3N2) were isolated from the human clinical sample 
kindly provided by Canton University Hospital (Geneva, 
Switzerland). Virus 1035wt (H1N1) was isolated from 
the human clinical material provided by Dr. Lee (Hong 
Kong). Influenza reassortants were obtained by classical 
reassortment in Vero cells and genotyped as described 
previously [16].
Propagation and titration of viruses 
Viruses were propagated in Vero cells in DMEM/Ham’s 
F12 medium containing 1 µg/ml of trypsin (Sigma, T4549). 
A hemagglutination assay (HA assay) was performed 
with a 0.5% suspension of chicken red blood cells. The 
infectious titer of viruses was determined by a limiting 
dilution assay or by a plaque assay in Vero cells with agar 
overlay containing DMEM/Ham’s F12 medium, 4  mM 
L-glutamine, 1  µg/ml of trypsin, 0.01% DEAE dextran 
(Pharmacia), 0.6% agar (Sigma) and expressed in TCID50/ml 
or plaque forming units (PFU), respectively. 
Mouse immunization
Four to six week old B6D2F1 hybrid mice (Charles 
River, Germany) were infected intranasally under ether 
anesthesia with 50  µl of virus containing cell culture 
supernatant. One or 3 days post infection, 4 mice from 
each group were sacrificed, the nasal turbinates and lungs 
were removed, homogenized and titrated for the presence 
of virus by a limiting dilution assay. The virus titer was 
expressed in log10TCID50/ml of 10% organ suspension. 
Mouse sera (4  animals per group) were collected three 
weeks after immunization. The antibody titers were 
measured by HAI assay and ELISA [17]. For the HAI assay, 
immune serum samples were treated with a receptor-
destroying enzyme (Denka, Japan) to remove unspecific 
inhibitors, according to the supplier’s recommendations.
Virus purification
The supernatant of infected cells was clarified by 
centrifugation at 3,500  g for 15  min at 4°C. Virus 
particles were purified by centrifugation in an SW28 rotor 
(Beckman) through a 30% sucrose cushion in NTE buffer 
(0.1 M NaCl, 0.01 M Tris HCl, 0.001 M EDTA, pH 7.4) at 
90,000 g for 150 min at 4°C. The pellet was resuspended 
in NTE buffer and loaded on the discontinuous gradient 
of 60 and 20% (w/v) sucrose in NTE buffer. The sucrose 
gradient was centrifuged in an SW41 rotor (Beckman) at 
210,000 g for 16 h at 4°C. The virus-containing band was 
isolated, diluted in NTE buffer, pelleted by centrifugation 
in an SW41 rotor at 210,000  g for 30  min at 4°C and 
resuspended in phosphate buffered saline (PBS).
Enzyme-linked immunosorbent assay (ELISA)
The ELISA protocol was performed as described 
previously [16]. For this purpose, sucrose purified 5389wt 
virus was adjusted to 20  HA units/50  µl in carbonate 
buffer (pH 9.6) and used for the coating of ELISA plates. 
Serial dilutions of pooled sera in PBS containing 1% 
bovine serum albumin (BSA) were added to the coated 
plates and incubated for 1  h at room temperature. 
After several washing steps, bound antibodies were 
detected with rabbit anti-mouse IgG conjugated with 
horseradish peroxidase (Sigma). Plates were stained 
with o-phenylendiamine as substrate, and absorbance at 
450 nm was measured. The cutoff values were determined 
as the mean of the negative control samples value plus 3 
standard deviations.
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Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS PAGE) and Western 
blot analysis
SDS PAGE of purified 5389wt virus preparation was 
carried out using Tris-Glycine 16% gels (Anamed). 
Western blotting was performed by the electrophoretic 
transfer of the proteins from the gel to a polyvinyl 
difluoride membrane (Millipore) for two hours at 400 mA. 
After overnight blocking in TPBS (PBS with 0.1% Tween 
20) containing 3% of skim milk, the membrane was cut 
into separate single lane pieces that were incubated for 
one hour with a pool of polyclonal mouse antisera raised 
against different viruses that were diluted 1:100 in TPBS 
buffer containing 1% of skim milk. After washing with 
TPBS, the membrane was incubated for 1 h with alkaline 
phosphatase labeled anti-mouse antibody (Sigma) 
diluted 1:10,000 in TPBS containing 1% of skim milk. 
The blots were developed in staining buffer (100 mM Tris 
HCl; 100 mM NaCl; 5 mM MgCl2, pH 9.5) with nitro blue 
tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate.
Determination of fusion pH by hemolysis
Sucrose purified viruses in PBS, adjusted to an HA titer 
of 1:128 (200 µl) were incubated in a 48-well plate on ice 
with 600 µl of 0.5% freshly washed human red blood cells 
(type 0, Rh negative) prepared in saline solution for 1 h 
to allow virus binding. The plate was then centrifuged at 
800 g for 3 min and 700 µl of supernatant were removed. 
Another 700 µl of sodium citrate buffered saline (0.15 M) 
was added at various pH, covering the range 5.0-6.2, and 
incubated for 1 h at 37°C. After centrifugation at 800 g 
for 3 min, 300 µl of supernatant were transferred to a 
flat-bottom 96-well plate. The amount of hemoglobin 
in the supernatants was determined by measuring the 
absorbance at 405  nm. The reported results are the 
mean values ± standard deviations of 3 repeats at the 
indicated pH.
Virus stability toward acidic pH
Influenza viruses were incubated in 0.15  M sodium 
citrate buffered saline with pH 5.2 at 37°C for different 
time intervals. At the appropriate time points, samples 
were placed on ice and neutralized with NaOH to pH 7.4. 
Subsequently, the TCID50 titer was determined for all of 
the samples in Vero cells and expressed in log10TCID50/ml. 
For the control sample, an equal amount of PBS was 
added instead of sodium citrate and the viruses were 
treated the same way.
Focus reduction assay
MDCK cell cultures in 96-well plates were inoculated with 
150 µl of serial twofold dilutions of amantadine (Sigma), 
ranging from 4 to 0.03  µg/ml in DMEM/Ham’s F12 
medium [18]. Then, 50 µl/well of virus with a multiplicity 
of infection (MOI) from 100 to 200 focus forming units 
were added to each well except the control well. After 
overnight incubation at 33°C without trypsin, cells were 
fixed with 4% paraformaldehyde for 1 h and permeabilized 
with a 0.2% solution of Triton X-100 in PBS for 20 min. 
All the steps were carried out at room temperature. Fixed 
cultures were immuno-stained for the expression of viral 
nucleoprotein by incubation for 1  h with monoclonal 
antibodies specific for the nucleoprotein of influenza 
A virus (kindly provided by Dr. Eva Varechkova at the 
Institute of Virology, Bratislava, Slovakia) followed by 
1  h of incubation with peroxidase-labeled anti-mouse 
antibodies (Sigma) and a 30  min incubation with 
precipitate-forming peroxidase substrate (True Blue, 
KPL). Horse serum (10%) plus 0.005% Tween 20 in PBS 
was used for the preparation of working dilutions of 
immuno-reagents. Foci were counted visually and the 
results were expressed as the percentage of inhibition. 
The reported results are the mean values ±  standard 
deviations of 3 replicate determinations at the indicated 
concentrations of amantadine.
Gene amplification and sequencing
Viral RNA was extracted from the tissue culture 
supernatant of infected cells using Trizol reagent 
(Invitrogen). C-DNAs were synthesized using M-MuLV 
reverse transcriptase (MBI). The M gene and three 
overlapping parts of the HA gene were amplified by 
PCR using specific primers (sequence available upon 
request). The PCR products were purified using a Gel 
Band Purification Kit (Amersham Pharmacia Biotech) 
and were sequenced at SEQLAB GmbH (Germany). The 
sequences were analyzed using Lasergene 99 software. 
The H3 numbering system was used throughout the 
study for influenza A viruses. The obtained sequence 
data for HA and M genes were submitted to the GenBank 
(Table 1). 
Table 1. Comparison of amino acid sequences of viruses used in this study.





7729/wt HA Vero AF382318.1 - -
1035/wt HA (HA2) Vero AF386776 10 Val
1035/wt HA (HA2) MDCK AF386777 10 Ile
5389/wt HA (HA2) Vero AF386773.1 3 Leu
5389/wt HA (HA2) MDCK AF386774.1 3 Phe
Sing/ca M (M2) Vero X08093.1 36, 43 Leu, Leu
5389/wt M (M2) Vero DQ299489.1 36, 43 Met, Ile
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Statistical analysis
The obtained data were analyzed using GraphPad 
Prism version 6.00 for Windows. The significance of the 
differences between the groups was determined by a 
non-parametric Mann–Whitney test. P-values of ≤0.05 
were considered significant. 
RESULTS
HA sequences of epidemic influenza viruses isolated 
in Vero cells
In order to avoid any receptor binding mutations 
induced by the avian cells of embryonated eggs, we used 
epidemic viruses isolated in Vero cells directly from the 
human clinical material for the construction of vaccine 
candidates. According to our data, enhanced virus growth 
in Vero cells might be accompanied by the occurrence of 
mutations in the HA, which increase the pH threshold of 
HA conformational change (pH of fusion or activation) 
[19]. In our previous paper we showed that viruses 
with an increased pH of activation are characterized 
by decreased infectivity in the mouse respiratory tract 
and reduced immunogenicity in ferrets after intranasal 
immunization [20, 21].
The HA sequences of both reassortants used for 
human immunization were identical to the sequences of 
the corresponding Vero-derived wild type parent strains. 
Therefore the consecutive studies were performed using 
the wild type viruses. Initially we analyzed the HA of wild 
type viruses for the presence of mutations in comparison 
to the original human viruses. We found that the HA 
sequence of Vero-derived 7729wt virus fully coincided 
with the HA sequence of virus present in the clinical swab 
(Table 1). In contrast, the HA of Vero-derived 1035wt 
virus differed from that of the clinical sample by a single 
mutation 10Ile→Val located at the fusion peptide of HA2 
subunit. It is known that mutations in the fusion peptide 
might increase the pH threshold of HA conformational 
change [22]. Therefore, as the next step in our study, we 
compared the pH of HA activation of the Vero-derived 
1035wt virus with that of the MDCK-derived 1035wt virus, 
which did not have any substitutions, in a hemolysis test.
The pH of the HA activation of Vero- and 
MDCK-derived 1035wt viruses
The pH of HA fusion was determined as the pH value at 
which the released hemoglobin was observed following 
the fusion of virus with human red blood cells. The results 
shown in Fig. 1A indicate that 50% of the fusion for the 
MDCK-derived 1035wt was observed at pH 5.5, while for 
the Vero-derived virus it was observed at pH 5.8. Therefore, 
mutation 10Ile→Val increases the threshold pH of HA 
activation of Vero-derived 1035wt virus by 0.3 pH units.
The stability of 1035wt and 7729wt viruses 
to acidic pH
Next, we compared the stability of 1035wt and 7729wt 
viruses toward acidic pH (pH 5.2). As shown in Fig. 2, the 
7729wt virus did not lose any infectious titer following 
incubation at pH 5.2 for 15 min, whereas the infectious 
activity of the 1035wt decreased by 1.75 log10TCID50/ml. 
Therefore, virus 7729wt appeared to be more stable 
toward the acidic pH than virus 1035wt bearing the 
mutation 10Ile→Val. Based on our previous observations, 
it is possible to suggest that substitution 10Ile→Val in 
the HA of vaccine strain might be the reason for the 
absence of an immune response after the immunization 
of humans. 
Besides mutations in HA, the reassortant gene 
constellation is known to affect virus properties [23-
28]. Thus it was shown that the incompatibility of HA 
with M1 and M2 proteins coded by the M gene leads 
to the impaired virus yield and induces changes of the 
virion morphology [29-31]. Therefore, we investigated 
the possible influence of the M gene origin on the 
immunogenicity of reassortant viruses.
Properties of 6/2 and 5/3 reassortants obtained from 
5389wt and Sing/ca viruses 
In order to investigate the influence of the M gene 
products on virus properties, the corresponding 
reassortants with two (HA and NA) or three (HA, NA 
and M) genes from the epidemic virus 5389wt (H1N1) 
and other genes from the Sing/ca master strain were 
generated. Virus 5389wt was isolated directly in Vero 
cells. The HA of Vero-derived virus 5389wt contained 
a single mutation 3Phe→Leu located at the HA fusion 
peptide when compared to the HA sequence of MDCK-
derived virus or clinical isolate. Both reassortants, despite 
the M gene origin, displayed similar growth in Vero cells. 
The infectious titers of both viruses were comparable to 
the titer of 5389wt and were 2.0  log10 TCID50/ml lower 
than that of Sing/ca (Fig. 3). These results indicate that 
the origin of the M gene had no influence on the growth 
of reassortants in Vero cells.
A comparison of the pH of HA fusion for the Vero-
derived 5389wt with that of MDCK-derived virus was 
performed by the hemolysis assay. We demonstrated 
that the HA of MDCK-derived 5389wt virus showed 50% 
of hemolytic activity at pH 5.7 while the HA of Vero-
derived virus at pH 6.0. (Fig. 1B). These data indicate that 
substitution 3Phe→Leu is also related to the increased 
pH threshold of the HA conformational change of Vero-
derived 5389wt virus by 0.3 pH units.
Growth of 6/2 and 5/3 reassortants in the mouse 
respiratory tract 
Next, we compared the growth of Vero-derived 5389wt 
and both 6/2 and 5/3 reassortants in the upper and lower 
respiratory tract of mice after intranasal immunization. 
As shown earlier, the master strain Sing/ca is replicated 
in the upper respiratory tract of animals but not in the 
lungs [16]. The epidemic virus 5389wt demonstrated 
a high replication activity in the mouse nasal 
turbinates (6.0  log10TCID50/ml) as well as in the lungs 
(5.5  log10TCID50/ml). Reassortants 6/2 and 5/3 grew to 
titers not exceeding 2.5  log10TCID50/ml in nasal tissues 
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Fig. 1. Fusogenic properties of Vero- and MDCK-derived viruses. (A) Fusogenic activity of 1035wt viruses. (B) Fusogenic activity of 5389wt 
viruses. The pH of HA fusion was determined as the value at which the released hemoglobin was observed following the fusion of the virus 
with human red blood cells. The amount of released hemoglobin was determined by measuring the absorbance at 405 nm. The reported 
results are the mean values ± standard deviation of 3 repeats at each pH for each virus. 
Fig. 2. The stability of 1035wt and 7729wt viruses toward acidic pH. Virus infectious titers were measured post incubation in 0.15 M 
sodium citrate buffered saline (pH 5.2) at 37°C from 5 to 15 min.
A
B
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of mice and were not detectable in the lungs of animals 
(Table  2). These results indicate that the origin of the 
M gene products does not have any effect on the virus 
growth in the respiratory tract of mice. 
The immune response induced by 6/2 and 5/3 
reassortants in mice
The immunogenicity of 6/2 and 5/3 reassortants 
was measured three weeks after a single intranasal 
immunization of mice by HAI and ELISA. The results 
showed that the highest immune response was induced 
by the 5389wt virus with GMT of 104 in HAI and GMT 
of 412 in ELISA (Table  2). Animals immunized with 
6/2 reassortant revealed no antibodies in the HAI test 
(GMT<4), while the GMT of antibodies measured by 
ELISA was equal to 75. In contrast, the titers of the 5/3 
reassortant-induced antibodies (GMT of 19.4 in HAI and 
180 in ELISA) were significantly higher than those for the 
6/2 reassortant. Thus, the 5/3 reassortant appeared to be 
more immunogenic than the 6/2 after single intranasal 
immunization of mice.
Next we determined the ratio of antibodies in mouse 
post infectious sera directed to the HA1 and HA2 
subunits based on the density of HA bands in a Western 
blot (Fig.  4). The ratio of HA2/HA1 antibodies induced 
by 5389wt virus was used as a reference point equal to 
1. It turned out that the 5/3 virus induced a comparable 
amount of antibodies binding to HA1 and to HA2 subunits 
with the HA2/HA1 ratio of 1.1. In contrast, the serum 
obtained after immunization with the 6/2 reassortant 
contained predominantly antibodies that recognized the 
HA2 subunit with the HA2/HA1 ratio of 1.7. These data 
indicate that upon replication in mouse cells the HA of 
6/2 reassortant was transformed partially to the low pH 
form with the exposed epitopes of HA2 subunit. 
One of the functions of the M2 protein is to preserve 
the native HA conformation during the transport 
through the trans-Golgi network [29, 31, 32], i.e. to 
keep the pH above the threshold of HA conformational 
change. When the activity of the M2 ion channel is low, 
the HA can change the conformation to the low pH form. 
The HA at low pH conformation is known to express 
more epitopes of the HA2 subunit that are hidden in the 
native HA conformation. Therefore, we suggested that 
the ion channel activity of the Sing/ca M2 protein is not 
sufficient to keep the mutant HA of 5389wt virus in a 
correct native conformation in the trans-Golgi network. 
To check this hypothesis, we compared the ion channel 
activities of 6/2 and 5/3 reassortants. 
M2 ion channel activity of 6/2 and 5/3 reassortants
Amantadine is an antiviral drug that inhibits influenza 
virus replication by blocking the M2 ion channel activity. 
The sensitivity of viruses to amantadine correlates 
with the ion channel activity of M2 protein [33-35]. We 
compared the M2 ion channel activity of 6/2 and 5/3 
reassortants by measuring their sensitivity to amantadine 
using the focus reduction assay. 
The obtained results showed that, although both 
reassortants were sensitive to amantadine, the 6/2 
reassortant appeared to be inhibited by amantadine to 
a greater extent than the reassortant 5/3 (Fig.  5). This 
result indicates that the M2 ion channel activity of Sing/
ca virus is lower than that of 5389wt.
The comparison of M2 protein sequences of Sing/
ca and 5389wt viruses revealed a difference in 7 amino 
acids. Two of them, 36Leu(Met) and 43Leu(Ile), are 
located in the transmembrane (TM) domain of the M2 
protein responsible for the ion channel activity (Fig. 6) 
[36]. 
Fig. 3. Growth of Sing/ca, 5389wt, 6/2 and 5/3 viruses in Vero cells. Vero cells were infected at an MOI of 0.01. The virus titers were 
determined at indicated time points after infection. The presented results are the mean values of 3 titrations. The difference between the 
Sing/ca virus and others is significant at 16, 40, and 64 h post infection. * indicates p<0.02 determined by a non-parametric Mann-Whitney 
test.
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Table 2. Immune response and replication capacity of 5389wt, 6/2 and 5/3 viruses in mice.
Virus Reproduction in mouse organs, log10TCID50/ml
a Serum reciprocal antibody titers, GMT
Nasal turbinates/day Lungs/day
3
HAI ELISA, total IgG
1 3
5389wt 4.5±0,3 6.0±0.4 5.0 ± 0.2 104 412
6/2 2.5±0.2 2.5±0.2 <1.5 2 75
5/3 2.5±0.2 2.5±0.2 <1.5 19.4b 180 
a Data are given as mean values for four mice.
b The difference between 6/2 and 5/3 reassortants is significant, p = 0.02 determined by a non-parametric Mann-Whitney test.
Fig. 5. Sensitivity of 6/2 and 5/3 reassortants to amantadine. Serial 2-fold dilutions of amantadine were added to MDCK cell cultures. 
Virus with an MOI ranging from 100 to 200 focus forming units was added to each well. Then cells were fixed, permeabilized and immuno-
stained with monoclonal antibodies specific for the nucleoprotein of influenza virus. The reported results are mean values ± standard 
deviation of 5 repeats at each concentration of amantadine for each virus. The difference is statistically significant. * indicates p < 0.01 
determined by a non-parametric Mann-Whitney test.
Fig. 4. Distribution of antibodies in mouse post infection sera interacting with HA1 and HA2 subunits.
Purified influenza virus 5389wt was subjected to SDS PAGE and Western blotting as described in Materials and methods. After blotting, 
the membrane was incubated with 1:100 diluted pool of 4 mouse antisera obtained after immunization with the 5389wt, 6/2 or 5/3 virus. 
M - molecular size marker. The ratio of HA2/HA1 was measured by density analysis. 
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DISCUSSION 
For many years, the isolation of influenza viruses from 
patient clinical material was done in embryonated eggs. 
Due to the prevailing regulations, only egg-derived 
viruses are used for the generation of vaccine seed viruses. 
Now, the National Influenza Centers can use MDCK-
derived viruses for the characterization of circulating 
influenza viruses because of the higher isolation rate of 
viruses achieved with this cell line [37-39]. Previously, we 
showed that HA sequences of cell-derived viruses (Vero 
and MDCK cell lines) are more similar to that of the 
original circulating human viruses than the sequences of 
egg-derived isolates [40]. That was the reason why the 
Vero-derived isolates were used for the generation of 
vaccine reassortants.
The reassortant of 7729wt (H3N2) on the backbone of 
Sing/ca was immunogenic in adult volunteers, while the 
vaccine strain generated with the surface proteins from 
1035wt (H1N1) failed to induce any antibodies detected 
by the HAI test [16]. Similarly, the 6/2 reassortant of 
5389wt (H1N1) virus was not immunogenic in mice. 
Both epidemic Vero-derived viruses 1035wt and 5389wt 
were found to contain the substitutions 10Ile→Val 
or 3F→L at the fusion peptide of HA2 subunit that 
led to the enhancement of the pH threshold of an HA 
conformational change by 0.3 pH units. Besides, virus 
7729wt, which has an HA sequence identical to that of the 
clinical isolate, appeared to be more stable toward acidic 
pH than mutant virus 1035wt. This finding is consistent 
with our previous observations that the increased pH of 
HA activation is related to the decreased virus stability 
toward acidic pH and elevated temperature, decreased 
virus infectivity and immunogenicity after the intranasal 
Fig. 6. Structure of the transmembrane domain of influenza virus M2 protein in complex with amantadine.(A) Side view. (B) Top view. 
Protein Data Bank model 3C9J was visualized using USCF Chimera v.1.10.2 [36]. Mutated amino acids are colored in green.
A
B
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immunization of mammals [20, 21]. Therefore, the 
decreased immunogenicity of reassortants obtained 
from 1035wt and 5389wt viruses might be induced by HA 
mutations that occurred in the course of virus isolation 
in the Vero cells.
It is known that the main reason for the restricted 
virus growth in Vero cells is that the late endosomes of 
Vero cells, where the fusion of viral and cell membranes 
takes place, have a relatively high pH that is higher than 
that in MDCK cells [15]. Thus, mutations 10Ile→Val and 
3Phe→Leu enable efficient virus replication in Vero 
cells. It is important to mention that the propagation of 
influenza viruses in MDCK cells as well as in eggs can also 
lead to the emergence of mutations which increase the 
pH of HA activation [19, 41] and decrease virus stability 
toward an acidic pH. 
The human airway epithelium is known to be slightly 
acidic (pH 5.5 to 6.9) because of the acidic secretion of 
the submucosal glands [42-47]. This feature is the innate 
mechanism of defense against pathogens. Moreover, as 
a response to organic dust or inflammation, the cells 
of human nasal airway epithelium start to release acid 
[48]. Thus, strains of the live influenza vaccine require 
a certain level of HA stability toward acidic pH for the 
efficient infection of the human upper respiratory tract.
Another factor that might compromise the 
immunogenicity of vaccine reassortant is the 
incompatibility of the HA and M genes originated from 
different viruses. We found that the 6/2 reassortant of 
5389wt (H1N1) virus on the backbone of the master strain 
Sing/ca induced antibodies that were detectable in ELISA 
but not in the HAI test, and were directed predominantly 
to the HA2 subunit. However, the 5/3 reassortant bearing 
the HA and M genes from the epidemic virus induced an 
equivalent amount of antibodies reacting with HA1 and 
HA2 subunits detectable in HAI. This result indicates 
that the HA of 6/2 reassortant was predominantly on 
the surface of virions and/or of infected cells in the 
low pH conformation with exposed HA2 epitopes. The 
incompatibility of the M gene of H2N2 virus with the 
HA gene of an avian virus with a polybasic cleavage site 
is well documented [29, 32, 49]. The authors of these 
publications have shown that the M2 protein of H2N2 
virus lacked sufficient ion channel activity to maintain 
the pH of the trans-Golgi network above the threshold 
necessary to preserve the native conformation of the 
avian virus HA with the polybasic cleavage site. The 
prerequisite for the HA conformational rearrangement 
in the trans-Golgi network is the HA intracellular 
cleavage to HA1 and HA2 subunits, which releases 
the fusion peptide. The HA of avian influenza viruses 
with a polybasic cleavage site is known to be cleaved 
intracellularly by furin. Recently, it was demonstrated 
that the HA of human H1N1 viruses is also cleaved 
intracellularly by TMPRSS2 protease (reviewed in [50]). It 
was shown that the acid sensitive HA of the (H1N1)pdm09 
virus is in the same way protected from the premature 
conformational changes during intracellular transport 
by the M2 ion channel [51]. Therefore, we can 
conclude that the M2 channel activity of Sing/ca virus 
is too weak to keep the pH of the trans-Golgi network 
above the threshold necessary to preserve the native 
conformation of the acid sensitive HA of Vero-derived 
5389wt virus. As a result, most of HA proteins changed 
the conformation to the low pH form and induced 
antibodies predominantly to the HA2 subunit in 
immunized animals. 
Although the sequence of M2 protein is known to 
be highly conserved among different influenza viruses, 
there are known variations of its structure that have 
an impact on M2 ion channel activity [33, 34, 52]. Two 
changes, Leu36→Met and Leu43→Ile, were revealed 
in the TM domain of Sing/ca virus compared to that of 
5389wt. The position 36 is in the immediate vicinity of 
H37 - the residue serving as the proton-selective filter 
of the M2 ion channel. The protonation of the H37 
residue is responsible for the channel activation [53-
55]. The second substitution (Leu43→Ile) is located 
within the H37xxxW41xxD44 motif of the channel, 
which is involved in the pore gating [53]. The side chain 
of amino acid L43 together with the side chains of Ile42 
and Leu40 participates in hydrophobic interactions 
with the membrane [54, 56]. It is highly probable that 
substitutions of these amino acids would influence 
the structure of the H37xxxW41xxD44 motif and 
consequently affect the conductance of the channel 
[57]. 
It is interesting to note that the sequences of the M2 
TM domains of the 7729wt (H3N2) and Sing/ca viruses 
are identical. Although the ion channel with this TM 
domain structure has low activity, the resulting pH level 
in the trans-Golgi network was probably high enough 
to prevent the conformational modification of the more 
stable HA of H3N2 virus. 
Hereby, the combination of the H2N2 virus M gene and 
HA with the elevated pH of activation could provoke an 
undesirable conformational change of the HA molecules 
during virus maturation and affect the immunogenic 
properties of the vaccine strain following the intranasal 
immunization. Interesting results were published by 
O’Donnell et al. who showed that the reassortants 
bearing just one M gene of A/Ann Arbor/6/60 ca (H2N2) 
master strain (the FluMist® vaccine) were characterized 
by the increased pH threshold of HA activation, 
decreased virus stability toward acidic pH, and restricted 
replication in the respiratory tract of vaccinated humans 
[58]. Unfortunately, the authors did not elucidate the 
mechanism of the observed activity and explained this 
phenomenon as a gene constellation effect. 
It is important to mention that we did not notice any 
significant difference in the reproduction capacity of 
6/2 and 5/3 reassortants in vitro. This could be explained 
by a relatively high pH (6.45 +/- 0.03) of the intra-Golgi 
network in Vero cells [59], which do not require a highly 
active ion channel. This observation is in accordance 
with the results obtained by Watanabe et al. who 
showed that a virus with an impaired TM domain grew 
efficiently in continuous cell lines, but demonstrated 
restricted growth in the mouse upper respiratory tract 
[60]. 
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Taken together, both the influenza virus HA stability 
and the compatibility of HA and M genes should be taken 
into consideration when constructing the reassortant 
vaccine strains for the live attenuated vaccines and 
selecting the substrate for the vaccine production. 
Application of reverse genetics for the construction of 
vaccine reassortants is of great benefit as it allows the use 
of the sequences of human influenza virus genes present 
in the clinical material without any adaptation mutations. 
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